Immunex to file Novantrone NDA for hormone refractory prostate cancer in first half of 1996.
Executive Summary
IMMUNEX TO FILE NOVANTRONE NDA FOR HORMONE REFRACTORY PROSTATE CANCER in the first half of 1996, Immunex CEO Edward Fritzky forecast Jan. 9 at the Hambrecht & Quist annual health care conference in San Francisco. Novantrone (mitoxantrone) currently is indicated for initial therapy of acute nonlymphocytic leukemia in adults. "In December, we had a favorable discussion with the FDA about our filing plan, and if all goes well with our final data analysis, we plan to file for Novantrone's use in hormone refractory prostate cancer in the first half of this year," Fritzky said.